Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Valentín García‐Gutiérrez, Alejandro Luna, Juan Manuel Alonso‐Domínguez, Natàlia Estrada, Concepción Boqué, Blanca Xicoy, Pilar Giraldo, Anna Angona, Alberto Álvarez‐Larrán, Fermín Sánchez‐Guijo,

Blood Cancer Journal · 2021 · 44 citations · 7 references

DOIFull text

Open access

Concepts

Abstract

Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance 1 , 2 , 3 . Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity 4 , 5 . Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses 6 , 7 , 8 .

References

7